FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Italy Fines Apple €98.6 Million Over App Store Dominance 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
WALTHAM, Mass., Oct. 24, 2016 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor conferences. The three conferences are:
- The Credit Suisse 25th Annual Healthcare Conference at The Phoenician in Scottsdale, Arizona on Monday, November 7 and Tuesday, November 8. Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, will present on November 8 at 8:30 AM MT and will also host meetings with investors.
- The Global Mizuho Investor Conference at The Omni Berkshire Place in New York, New York on Monday, November 14. Tim Pearson, EVP and CFO of TESARO, will participate in meetings with investors.
- The Raymond James Boston Fall Investors Conference at The State Room in Boston, Massachusetts on Tuesday, November 15. Tim Pearson, EVP and CFO of TESARO, will participate in meetings with investors.
A live webcast of the presentation at the Credit Suisse conference will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. An archived replay of this webcast will be available on the Company’s website for 14 days following the conference.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact: Jennifer Davis 1.781.325.1116 [email protected]
